Avulux lands FDA de novo classification for light-sensitive migraine lenses

Avulux’s lens technology uses a optical filters to block up to 97% of blue, amber, and red light while letting soothing green light through. Avulux’s lens technology uses a optical filters to block up to 97% of blue, amber, and red light while letting soothing green light through. Research indicates that over 45 million people in the US are affected by episodic migraine, while up to 90% of people living with the neurological condition cite light sensitivity as a symptom. Credit: Runawayphill/Shutterstock.com Avulux has obtained de novo marketing authorisation from the US Food and Drug Administration (FDA) for its optical…

Source: Medical Device Network